Etavopivat
- Generic Name
- Etavopivat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O6S
- CAS Number
- 2245053-57-8
- Unique Ingredient Identifier
- V4E0A9M44Q
- Background
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Phase 2
Active, not recruiting
- Conditions
- Sickle Cell DiseaseThalassemia
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04987489
- Locations
- 🇺🇸
[Legal] Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Oakland Benioff ChildHosp, Oakland, California, United States
🇺🇸[Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County, Orange, California, United States
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Phase 3
Active, not recruiting
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT04624659
- Locations
- 🇫🇷
Hospices Civils de Lyon-Hopital Edouard Herriot, Lyon, France
🇩🇪Univertatsklinikum Frankfurt, Frankfurt, Germany
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath